Clinical Trial

Cannabis for Palliative Care in Cancer

Study acronym: ARCTiC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-02-16; most recent amendment 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2024-07-17
Trial Details
NCT Number NCT06266611
Lead Sponsor University of Colorado, Boulder
Conditions Sleep, Anxiety, Depression, Pain
Enrollment 185 participants
Start Date 2024-09-16
Primary Completion 2028-05-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-01